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Background: A relatively high proportion of deaths in dialysis patients occur suddenly and
unexpectedly. The incidence of sudden cardiac death (SCD) in non-dialysis advanced chronic
kidney disease (CKD) stages has been less well investigated.
Objective: This study aims to determine the incidence and predictors of SCD in a cohort of
1078  patients with CKD not yet on dialysis.
Methods: Prospective observational cohort study, which included patients with advanced
CKD not yet on dialysis (stage 4–5). The association between baseline variables and SCD was
assessed using Cox and competing-risk (Fine and Gray) regression models. Demographic,
clinical information, medication use, and baseline biochemical parameters of potential
interest were included as covariates.
Results: During the study period (median follow-up time 12 months), 210 patients died (19%),
and  SCD occurred in 34 cases (16% of total deaths). All-cause mortality and SCD incidence
rates were 113 (95% CI: 99–128), and 18 (95% CI: 13–26) events per 1000 patient-years respec-
tively. By Cox regression analysis, covariates signiﬁcantly associated with SCD were: Age,
comorbidity index, and treatment with antiplatelet drugs. This latter covariate showed a
beneﬁcial effect over the development of SCD. By competing-risk regression, in which the
competing event was non-sudden death from any cause, only age and comorbidity index
remained signiﬁcantly associated with SCD.
Conclusions: SCD is relatively common in non-dialysis advanced CKD patients. SCD was
closely related to age and comorbidity, and some indirect data from this study suggest that
unrecognized or undertreated cardiovascular disease may predispose to a higher risk of SCD.©  2016 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Muerte  súbita  en  pacientes  con  enfermedad  renal  crónica  avanzada
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r  e  s  u  m  e  n
Antecedentes: Una alta proporción de fallecimientos en pacientes tratados mediante diálisis
ocurre de forma súbita e inesperada. La incidencia de muerte súbita (MS) en pacientes con
enfermedad renal crónica (ERC) en estadios prediálisis es menos conocida.
Objetivos: Determinar la incidencia y factores asociados a la MS en una cohorte de 1.078
pacientes con ERC avanzada.
Métodos: Estudio de cohortes prospectivo y de observación, que incluyó a pacientes con
ERC estadio 4-5 prediálisis. La asociación entre las variables basales y la MS  fue analizada
mediante modelos de regresión de Cox y de competencia de riesgo (Fine y Gray). Los datos
demográﬁcos, clínicos, la medicación y los parámetros bioquímicos basales de potencial
interés fueron incluidos como covariables en el análisis predictivo.
Resultados: Durante el periodo de estudio (mediana de seguimiento 12 meses), fallecieron 210
pacientes (19%) y de forma súbita 34 casos (16% total de muertes). Las tasas de incidencia
de  muerte por cualquier causa y de MS fueron: 113 (IC 95%: 99-128) y 18 (IC 95%: 13-26)
eventos por 1.000 paciente-an˜os respectivamente. Mediante análisis de regresión de Cox, la
edad,  el índice de comorbilidad y el tratamiento con antiagregantes plaquetarios fueron las
covariables que se asociaron signiﬁcativamente con MS. Esta última covariable mostró un
efecto beneﬁcioso sobre el desarrollo de MS. En los modelos de regresión por competencia
de  riesgo, en los que el evento competidor fue la muerte no súbita por cualquier causa, solo
la  edad y el índice de comorbilidad se asociaron signiﬁcativamente con la MS.
Conclusiones: La MS es relativamente frecuente en pacientes con ERC prediálisis. La MS  se
asoció signiﬁcativamente con la edad y la comorbilidad, y varios datos indirectos de este
estudio muestran que un infradiagnóstico o infratratamiento de la enfermedad cardiovas-
cular podría predisponer a un mayor riesgo de MS.
©  2016 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/
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ardiovascular disease is a leading cause of mortality in
atients with chronic kidney disease (CKD), and a large propor-
ion of these deaths occur suddenly and unexpectedly.1–4 The
athogenetic mechanisms behind the association between
KD and sudden cardiac death (SCD) are incompletely under-
tood. Ischemic, structural and electro-physiologic changes of
he heart are common in CKD, and all of these conditions pre-
ispose to a higher risk of developing lethal arrhythmias.1–4
urthermore, hyperkalemia, major shift of electrolytes, and
emodynamic instability associated with haemodialysis may
rigger cardiac arrhythmias.1–4 In fact, the majority of studies
bout the association of SCD and CKD have been focused on
atients undergoing haemodialysis.5–10
The incidence of SCD in pre-dialysis stages of CKD has been
ess well investigated. In patients diagnosed with ischemic
eart disease or heart failure, a decreased GFR is associated
ith an increased risk of SCD.11–14 However, to our knowledge,
here have been no studies addressing the incidence of SCD in
nbiased pre-dialysis CKD populations.
Therefore, we  conducted a study to determine the inci-
ence of SCD in a prospective incident cohort of 1078 patients
ith advanced CKD patients not yet on dialysis. Factors asso-
iated with SCD were determined using prediction models,
hich accounted for competing causes of death.by-nc-nd/4.0/).
Material  and  methods
Patients
Between January 2000 and October 2013, 1078 incident
patients admitted to the advanced chronic kidney disease
outpatient clinic of our hospital were included in this prospec-
tive observational cohort study. All patients were older
than 18 years, they had CKD stage 4 or 5 pre-dialysis,
and none of them had previously received a kidney trans-
plant. There were no other exclusion criteria. Demographic,
clinical information, and medication use were obtained
through the medical records and anamnesis. Co-morbidity
was assessed at baseline, using the Davies index,15 and
patients were categorized according to their comorbidity
scores as having: absence, mild-moderate or severe co-morbid
conditions.
The following baseline biochemical parameters, measured
by standard laboratory techniques, were included: serum cre-
atinine, potassium, phosphate, calcium, bicarbonate, PTH,
albumin, and C-reactive protein. The abbreviated Modiﬁca-
tion of Diet in Renal Disease equation (MDRD) was used to
estimate GFR.16 Chronic hyperkalemia was considered when
serum potassium levels were greater than 5.5 meq/l in at least
50% of samples from an individual patient, measured through-
out the study period.
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Outcome  measures
Causes of death were categorized as: sudden cardiac death,
non-sudden cardiac death, and non-cardiac death.
Sudden cardiac death (SCD) was deﬁned as an unexpected
natural death due to cardiac or unknown causes, occurring
within 1 h after the onset of symptoms; or sudden unexplained
death during sleep.
Sudden deaths in patients with end-stage renal disease
who  rejected dialysis or were on palliative therapy were not
considered as SCD.
All SCD were conﬁrmed in interviews with the patient’s
physician or family members.
Non-sudden cardiac deaths included those due to ischemic
heart diseases or heart failure, which had an expected course
of events. The rest of causes of death were grouped as non-
cardiac death.
Patients in pre-dialysis CKD stages were followed from the
time of the study entry until death, loss to follow-up, initiation
of dialysis, or end of follow-up on February 2014.
Statistical  analysis
Rates of all-cause and speciﬁc causes of mortality are
expressed as events per 1000 patient/years and their 95% con-
ﬁdence intervals (CI). Parametric and non-parametric tests
were chosen as appropriate for descriptive comparisons of
continuous variables, and Pearson’s chi-squared or Fisher
exact test for categorical variables.
The association between baseline variables and SCD in pre-
dialysis patients was assessed using Cox proportional hazards
models that censored for other causes of death. Age, gen-
der, comorbidity index, diabetes, serum potassium, chronic
hyperkalemia, serum levels of phosphate, calcium, bicarbon-
ate, albumin, PTH, C-reactive protein, and medication use
(statin, aspirin, betablockers, etc.) were the covariates selected
according to their clinical interest and plausible potential to
act as confounders. Due to the skewed frequency distribution
of serum C-reactive protein values, they were analyzed as their
logarithm (log)-transformed values, and also as a dichotomous
variable (upper tertile vs. mid  or lower tertiles).
Models were ﬁt using Efron approximation for handling
ties. The proportional hazard assumption was checked graph-
ically (log–log Kaplan–Meier curves) for all covariates. The age
of patients did not satisfy the assumption of linear relation-
ship with log cumulative hazard. All patients who died from
SCD were older than 65 years. Thus, additional analyses with
models stratiﬁed according to the age of the study patients
(above or below the median), were carried out. To estimate
the cumulative incidence of SCD while accounting for the
competing risks of dying from other causes, a competing-
risk proportional hazards regression model was built using
the method of Fine and Gray.17 The same baseline covari-
ates selected in the Cox model were also re-analyzed with the
competing-risk model, and the subhazard ratios (SHR) were
estimated.Descriptive statistics is presented as mean and standard
deviation, or median and interquartile ranges (IQR) for con-
tinuous variables, and absolute values and percentages for
categorical variables. A p-value p < 0.05 was considered to be;3 6(4):404–409
signiﬁcant. All p-values are reported two-sided. Analyses were
performed using IBM SPSS Statistics 21.0 (IBM Corp. Armonk,
NY, USA), and STATA 11.1 (StataCorp, TX, USA).
Results
Patient  characteristics  and  mortality
The clinical characteristics of the whole group and subgroups
according to outcome status in the pre-dialysis follow-up
period are listed in Table 1.
Median pre-dialysis follow-up time was 12 months (IQR
5–27 months). During this period, 210 patients died (19%), and
63 were lost to follow-up (6%).
Sudden cardiac death (SCD) occurred in 34 cases (3% of total
study patients; 16% of total deaths in pre-dialysis CKD stages).
All-cause mortality, SCD, and non-sudden cardiac death
incidence rates were: 113 (95% CI 99–128), 18 (95% CI 13–26) and
44 (95% CI 35–54) events per 1000 patient-years, respectively.
Patients who died from SCD were predominantly elderly
men  with abundant comorbid conditions, mainly diabetes,
cardiovascular disease and COPD (Table 1). There were no
statistically signiﬁcant differences in the medians of plasma
C-reactive protein levels across subgroups. Median PTH level
in the SCD subgroup was slightly lower, but statistically sig-
niﬁcant, than that of survivors (Table 1).
Despite the fact that patients who died from SCD had
high scores of comorbidity, they seemed to be less frequently
treated with HMG-CoA reductase inhibitors, antiplatelets
drugs, diuretics or ACE inhibitors and/or ARBs than the sub-
group of patients who died from non-sudden cardiac diseases.
In the SCD subgroup, baseline serum potassium levels were
lower and the percentage of patients with chronic hyper-
kalemia smaller than the rest of subgroups, although this
difference was only statistically signiﬁcant with respect to
survivors (Table 1).
Predictors  of  sudden  cardiac  death  in  pre-dialysis  CKD
stages
By non-stratiﬁed Cox regression analysis, covariates signiﬁ-
cantly associated with SCD were: age, comorbidity index, and
treatment with antiplatelet drugs (Table 2) (Fig. 1). This latter
covariate showed a weak, although signiﬁcant beneﬁcial effect
over the development of SCD.
Neither log-transformed C-reactive protein levels, nor their
upper values (third tertile) were associated with SCD.
When Cox regression was stratiﬁed by the median age
of patients (above or below 69 years), age was no longer a
signiﬁcant predictor (HR 1.06; 95% CI 0.98–1.15; p = 0.09), but
comorbidity index (HR 2.59; 95% CI 1.25–5.36; p = 0.010) and
antiplatelet drug therapy (HR 0.39; 95% CI 0.16–0.92; p = 0.031)
remained signiﬁcantly associated with SCD.
By competing-risk regression based on Fine and Gray’s
proportional subhazards model, in which the competing
event was non-sudden death from any cause, only age and
comorbidity index remained signiﬁcantly associated with SCD
(Table 2).
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Table 1 – Clinical and biochemical characteristics of patients according to outcome status.
Alive Non-cardiac death Sudden cardiac
death
Non-sudden
cardiac death
Total
Patients, N (%) 868 (81) 95 (9) 34 (3) 81 (8) 1078
Age, years 62 ± 15a 75 ± 9 77 ± 4 75 ± 7 65 ± 15
Men, % 54 48 65 59 54
Body Mass Index, kg/m2 29.2 ± 5.8 29.3 ± 6.3 27.8 ± 5.2 28.6 ± 5.7 29.1 ± 5.8
Comorbidity index, %
Absence 39b 8 15 7 33
Mild-moderate 50 73 44 50 51
Severe 11 19 41 43 16
Diabetes, % 34c 38 44 59 37
Previous history of coronary
artery diseases, %
12c 16 27 44 15
Previous history of
peripheral vascular
diseases, %
17c 22 44 47 21
Previous history of heart
failure, %
14c 24 35 37 17
Previous history of chronic
obstructive pulmonary
disease, %
10c 12 27 20 12
eGFR, ml/min 13.9 ± 4.8d 15.8 ± 4.5 16.7 ± 5.6 17.5 ± 5.3 14.4 ± 4.9
Hemoglobin; g/dl 11.4 ± 1.7 11.2 ± 1.7 11.5 ± 1.6 11.5 ± 1.9 11.4 ± 1.7
Serum potasium, meq/l 5.1 ± 0.7 4.9 ± 0.7 4.7 ± 0.5e 4.9 ± 0.7 5.1 ± 0.7
Chronic hyperkalemia
(potasium > 5.5 mmol/l), %
26 17 6f 17 24
Serum phosphate; mg/dl 4.8 ± 1.2d 4.4 ± 0.9 4.2 ± 0.7 4.3 ± 0.8 4.7 ± 1.1
Total serum calcium; mg/dl 9.1 ± 0.9 9.2 ± 0.7 9.4 ± 0.6 9.3 ± 0.7 9.2 ± 0.8
Serum bicarbonate; meq/l 21.3 ± 3.8g 22.6 ± 3.5 21.7 ± 3.8 22.9 ± 5.2 21.6 ± 5.2
Serum albumin; g/dl 3.89 ± 0.54g 3.75 ± 0.55 3.85 ± 0.38 3.70 ± 0.70 3.86 ± 0.55
C-reactive protein*; mg/l 3.68 [1.29–9.31]d 6.06 [2.25–16.49] 4.15 [1.63–15.03] 5.56 [2.05–12.15] 3.89 [1.44–10.52]
Serum PTH*; pg/ml 215 [122–385] 207 [99–365] 138 [98–230]h 155 [79–279] 207 [112–374]
HMG-CoA reductase
inhibitor, %
54  39 32f 51 52
Aspirin or other
antiplatelets, %
30 36 38i 59 33
EPO, % 63 67 62 62 63
Betablockers, % 25 21 27 31 25
Diuretics, % 59 61 68 75j 61
Oral anticoagulation, % 6 8 6 19j 7
ACEI/ARB, % 76 55 59f 67 73
∗ Expressed as median and I.Q. ranges.
a p<0.0001 alive vs. rest of subgroups; Scheffé test.
b p<0.0001 alive vs. rest of subgroups; Chi-square test.
c p<0.0001 alive vs. SCD or non-SCD subgroups; Chi-square test.
d p<0.01 alive vs. rest of subgroups; Scheffé test.
e p<0.01 SCD vs. alive; Scheffé test.
f p<0.01 SCD vs. alive; Fisher exact test.
g p<0.05 non-SCD vs. alive; Scheffé test.
h p<0.05 SCD vs. alive; Mann-Whitney test.
i p<0.05 SCD vs. non-SCD; Fisher exact test.
D
I
a
a
d
mj p<0.01 non-SCD vs. alive; Fisher exact test.
iscussion
n this study, we  show that the incidence of SCD among
dvanced CKD population not yet on dialysis is relatively high,
ccounting for 16% of total deaths and more  than 29% of car-
iovascular mortality.
Elderly male patients with high comorbidity burden,
ainly diabetes and cardiovascular diseases, were the majorclinical characteristics associated with SCD in pre-dialysis
CKD stages.
Previous information about SCD incidence in nondialysis
CKD population has been derived from subgroup analyses of
clinical trials designed to evaluate the efﬁcacy of implantable
11,12cardioverter-deﬁbrillators, or from CKD patients diag-
nosed with ischemic heart disease o heart failure.13,14
Although the total number of participants with CKD stage
4–5 included in these studies has been rather small, the
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Table 2 – Cox regression and competing-risk regression models for sudden cardiac death in the pre-dialysis study
population.
Cox model* Competing-risk model**
HRa (95% CI) p SHRb (95% CI) p
Age, years 1.12 (1.06–1.18) <0.0001 1.11 (1.07–1.15) <0.0001
Comorbidity Index, (0,1,2) 2.79 (1.35–5.75) 0.005 2.34 (1.05–5.21) 0.037
Antiplatelet drugs, (0,1) 0.42 (0.18–0.97) 0.043 – –
a Hazard ratio and 95% conﬁdence intervals (CI).
b Subhazard ratio and 95% conﬁdence intervals (CI).
∗ Covariates not in equation but with statistical signiﬁcance p < 0.10: male
∗∗ Covariates not in equation but with statistical signiﬁcance p < 0.10: antip
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Fig. 1 – Cumulative incidence probability for sudden cardiac
death according to baseline comorbidity index.
edged. The study was single center, and the cohort included,
although largely representative of the local population, was,unanimous conclusion of all of these studies has been that
SCD risk increases in parallel with the worsening of renal
function.11–14
In the study of Pun et al.,14 which included 175 patients
with eGFR <15 ml/min not on dialysis, the SCD rate was of
12.6 events per 1000 patient-years, incidence lower than that
we have observed in our patients. Notwithstanding, patients
included in the Pun et al. study were younger (median age 61
years) than our study population (median age 69 years old).
The age of patients is a key determinant of SCD risk, as we
have demonstrated in our study, and this feature may explain
the variability of SCD rates between studies.
In the general population in Europe, the incidence of
SCD is approximately of 4 cases per 1000 patient/years,18 and
among the population aged 60 years or over the incidence
increases up to 8 cases per 1000 patient/years.19 The inci-
dence of SCD in our study patients was much higher than
that observed in the general population, but lower than that
observed in patients undergoing haemodialysis (17–28 cases
per 1000 patient-years).
Both subgroups of patients who  died from cardiovascu-
lar diseases (SCD and non-SCD) showed similar co-morbidity
burden. However, those who  died from SCD were being
treated less frequently with drugs commonly used for preven-
ting acute cardiovascular events. This ﬁnding was especially
remarkable with the use of aspirin or other antiplatelet drugs,
covariate that eventually became a signiﬁcant predictor of SCD
in Cox regression models. (HR = 2.05); diuretics (HR = 2.09).
latelet drugs (SHR = 0.45).
Underutilization of antiplatelet drugs in these patients may
be related to contraindications for their use, or due to a lack
of an appropriate diagnosis of ischemic heart disease, as it
is suggested by the smaller percentage of patients with pre-
vious history of coronary artery disease in those who  died
from SCD than that of those who died from other cardio-
vascular diseases. All these data suggest that unrecognized
or undertreated cardiovascular disease in CKD patients may
predispose to a higher risk of SCD.
Twenty-four percent of our study patients showed chronic
hyperkalemia, however, those who died from SCD had lower
mean baseline serum potassium levels, and had less fre-
quently chronic hyperkalemia than survivors.
Although hyperkalemia is a dreadful complication in end-
stage renal disease that can lead to cardiac arrhythmias and
SCD, mild to moderate hyperkalemia, commonly seen in non-
dialysis CKD patients, does not seem to be associated with
serious adverse events.20 Unlike hyperkalemia, hypokalemia
has been shown to be associated with greater all-cause mor-
tality in nondialysis CKD patients.20 In the present study,
hypokalemia was only observed in 19 patients and none of
them died from SCD.
In this study, we  have not found a signiﬁcant association
between C-reactive protein (CRP) and SCD. The medians of CRP
levels were higher in the subgroups of patients who  died than
that of survivors, however, CRP levels were not signiﬁcantly
different among subgroups according to the cause of death. In
other studies in patients on dialysis,6,10 CRP and serum albu-
min  concentrations have been shown to be associated with a
higher risk of SCD.
Age and comorbidity are variables strongly related with all-
cause mortality, and therefore, their association with a speciﬁc
cause of death can be overestimated if competing risk is not
taken into account. In this study, we applied a competing-
risk analysis using the Fine and Gray method as described by
Putter et al.,17 which estimates the cumulative incidence of
SCD while accounting for the competing risks of dying from
other causes. With this more  rigorous method of analysis, age
and comorbidity index remained signiﬁcantly associated with
SCD, although treatment with antiplatelet drugs lost the sta-
tistical signiﬁcance.
Potential limitations of this study need to be acknowl-however, ethnically homogenous (Caucasian). Some clinical
characteristics that could be important in predicting SCD, such
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s electrocardiogram abnormalities, left ventricular hypertro-
hy, etc., were not available in all patients. With the exception
f serum potassium levels, we  only used baseline measure-
ents to determine the association with SCD and not changes
n clinical parameters over time. Necropsies were not per-
ormed in those who died from SCD, thus precluding more
ccurate information about the cause of death.
In conclusion, SCD accounted for 16% of global mortality of
atients with advanced CKD not yet on dialysis, with an inci-
ence rate much higher than that of the general population.
CD was closely associated with age and comorbidity, and
ome indirect data from this study suggest that unrecognized
r undertreated of cardiovascular disease may predispose to
 higher risk of SCD.
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